GlassScriptPhysician profile
Erin A Duff
NPI 1629329867
$2,723.57
in general payments reported to CMS, 2019-2025
24 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $941 · 2022: $844 · 2023: $446 · 2024: $227 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889 · Entertainment: $48.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.48 |
| Entertainment | $48.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $573.76 | 2021-2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $217.38 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $188.48 | 2021-2022 | |
| Amgen INC. | $165.68 | 2022-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $159.44 | 2022-2024 | |
| Grifols USA, LLC | $157.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $155.56 | 2022-2025 | Verquvo, Steglatro |
| Genzyme Corporation | $155.11 | 2021-2022 | |
| Boston Scientific Corporation | $114.18 | 2023-2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.10 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.53 | 2021-2023 | |
| Electromed, INC. | $89.19 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $88.64 | 2021-2022 | |
| United Therapeutics Corporation | $79.05 | 2021 | |
| Edwards Lifesciences Corporation | $64.95 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.24 | 2022-2025 | Caplyta |
| Keystone Dental INC. | $48.79 | 2025 | |
| Novo Nordisk INC | $45.50 | 2023-2024 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $44.07 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.56 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $27.40 | 2023 | Rexulti |
| Abbott Laboratories | $23.91 | 2023 | Cardiomems |
| Pfizer INC. | $16.27 | 2023 | |
| Exact Sciences Corporation | $16.05 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Duff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.